Expert Rev Vaccines . Dendritic cell-based vaccine: the state-of-the-art vaccine platform for COVID-19 management

[tetano]

Expert Rev Vaccines


. 2022 Aug 5.
doi: 10.1080/14760584.2022.2110076. Online ahead of print.
Dendritic cell-based vaccine: the state-of-the-art vaccine platform for COVID-19 management


Vivek P Chavda ¹ , Aayushi B Patel ² , Lalitkumar K Vora ³ , Vasso Apostolopoulos ⁴ , Bruce D Uhal ⁵



Affiliations

• PMID: 35929957
• DOI: 10.1080/14760584.2022.2110076

Abstract

Introduction: A correlation between new coronaviruses and host immunity, as well as the role of defective immune function in host response, would be extremely helpful in understanding coronavirus disease (COVID-19) pathogenicity, and a coherent structure of treatments and vaccines. As existing vaccines may be inadequate for new viral variants emerging in various regions of the world, it is a vital requirement for fresh and effective therapeutic alternatives.
Area covered: Immunotherapy may give a viable protective option for COVID-19, a disease that is currently a big burden on global health and economic systems. Herein, we have outlined three dendritic cell (DC)-based vaccines for COVID-19 which are in human clinical trials and have shown encouraging outcomes.
Expert opinion: With existing knowledge of the virus, and the nature of DC, DC-based vaccines may be proven to be effective in inducing long-lasting protective immunity, especially T cell responses.

Keywords: COVID-19; DC; SARS-CoV-2; dendritic cell; immunotherapy; the lentiviral vaccine; vaccine.